Biosite BNP (B-type natriuretic peptide) HF (heart failure) test:
This article was originally published in Clinica
Executive Summary
Expanding the indications for its heart failure (HF) blood test, Biosite has gained US FDA 510(k) clearance to use its Triage BNP (B-type natriuretic peptide) test as a means of helping physicians assess the risk of mortality or re-hospitalisation in patients with the condition. The San Diego, California firm has already received US clearance to use the test to help diagnose HF, assess disease severity and for risk stratification of patients with acute coronary syndromes.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.